预约演示
更新于：2025-08-29
Changsha Jingyi Pharmaceutical Technology Co., Ltd
更新于：2025-08-29
概览
标签
其他疾病
神经系统疾病
皮肤和肌肉骨骼疾病
化学药
小分子化药
疾病领域得分
一眼洞穿机构专注的疾病领域
技术平台
公司药物应用最多的技术
靶点
公司最常开发的靶点
关联
靶点 |
作用机制 |
在研机构 |
原研机构 |
在研适应症 |
非在研适应症 |
最高研发阶段 |
首次获批国家/地区 |
首次获批日期 |
靶点 |
作用机制 |
在研机构 |
原研机构 |
在研适应症 |
非在研适应症 |
最高研发阶段 |
首次获批国家/地区 |
首次获批日期 |
靶点 |
作用机制 |
在研机构 |
原研机构 |
在研适应症 |
非在研适应症 |
最高研发阶段 |
首次获批国家/地区 |
首次获批日期 |
CTR20251924
KEM2102凝胶贴膏在中国健康志愿者中多次给药的安全性、耐受性及药代动力学研究
CTR20251365
双氯芬酸二乙胺乳胶剂人体生物等效性研究
CTR20250998
酮洛芬凝胶人体生物等效性研究
100 项与 长沙晶易医药科技股份有限公司 相关的临床结果
登录后查看更多信息
登录后查看更多信息
2025-08-01Drug Delivery and Translational Research
Development and in vitro/in vivo evaluation of taste-masked orodispersible films of dapoxetine hydrochloride using ion exchange resins
Article
作者: Yan, Peng ; Ding, Jinsong ; Zhang, Hailong ; Zhou, Ying ; Zhao, Xiangcheng ; Yang, Yan
Dapoxetine hydrochloride tablets are the most commonly used drug for the treatment of premature ejaculation (PE). However, the tablets must be taken with water 1-3 h before sexual activity, which makes the medication intake conspicuous and inconvenient. This study aimed to develop taste-masked orodispersible films (ODFs) of dapoxetine hydrochloride using ion exchange resins. It was found that the based-Kyron T-134 resin complex achieved a high drug loading of 75.9 ± 1.4%, establishing the mass ratio of dapoxetine hydrochloride to Kyron T-134 at 2:1, and adjusting the solution pH to 5.4 ± 0.05. The effect of pH on the drug loading of the resin was initially characterized by SEM, while the binding mechanism between dapoxetine hydrochloride and the resin was investigated by XRD, DSC, and FTIR. The ODFs exhibited favorable mechanical properties and palatability. Meanwhile, the drug release in both the ODFs and commercially available tablets Priligy® could reach 100.8% of the drug over 15 min in a simulated gastric fluid with pH 1.2 HCl. Furthermore, pharmacokinetic studies conducted in healthy volunteers demonstrated that the ODFs were bioequivalent to Priligy®. Therefore, this ODFs, characterized by its pleasant taste and water-free administration, offer a novel and convenient oral formulation for patients with PE, thereby enhancing patient compliance.
2025-06-01INTERNATIONAL JOURNAL OF PHARMACEUTICS
Development of long-acting imidafenacin transdermal patches with high drug loading based on solid dispersion technology
Article
作者: Yan, Peng ; Ding, Jinsong ; Zhang, Hailong ; Lin, Jianing
Imidafenacin tablets are the first-line drug for the treatment of overactive bladder (OAB). However, the tablets need to be taken twice daily for up to 3-6 months, which highly reduces patient compliance. This study aimed to develop a long-acting imidafenacin transdermal patch (LAITP) with high drug loading using amorphous solid dispersion technology (ASD). ASD, consisting of polyvinyl pyrrolidone and imidafenacin, not only significantly increased the drug loading in the patch, but also inhibited drug crystallization. Furthermore, the formation mechanism of ASD was systematically elucidated using SEM, XRD, DSC, FT-IR, and molecular docking. The LAITP was optimized through single-factor investigations and ternary phase diagram analysis. It was confirmed by SEM and confocal Raman microscopy that ASD was a spherical microparticle with a size of 28.62 ± 8.91 µm in LAITP. Notably, under long-term and accelerated conditions of 3 months, the LAITP exhibited excellent stability to ensure the reliability of quality. Importantly, human pharmacokinetic studies demonstrated that LAITP with low skin irritation and favorable adhesion properties prolonged sustained effective plasma concentration in comparison to commercial tablets (Staybla®), reducing the frequency of administration and thereby improving patient compliance, which is expected to be a promising treatment option for patients with OAB.
2025-05-30International Journal of Lower Extremity Wounds
Correlation of Wound Prognosis with serum IL-6, ICAM-1 and sST2 in Patients with Diabetic Foot and Construction of a Nomogram Model.
Article
作者: Guo, Yu ; Zhou, Wenhu ; Zhou, Yali ; Hu, Changping
Diabetes foot (DF) is one of the most serious chronic complications of diabetes. This study explored the relationship between serum interleukin-6 (IL-6), intercellular adhesion molecule-1 (ICAM-1) and soluble suppression of tumorigenicity 2 (sST2) and wound prognosis in 210 DF patients between January 2019 and January 2024. 210 DF patients were divided into the good prognosis (n = 147) and poor prognosis (n = 63) group according to the prognosis. Comparative analysis revealed that levels of serum IL-6, ICAM-1 and sST2 in the poor prognosis group were all higher than those in the good prognosis group significantly (P < .05). Multivariate logistic regression identified these 3 biomarkers as independent risk factors for poor wound healing (P < .05). Positive correlations between serum IL-6 (r = 0.269), ICAM-1 (r = 0.302), sST2 (r = 0.289) levels and poor prognosis were confirmed through Pearson's correlation analysis. A prediction model was established to analyse their predictive value. The training and validation sets ROC curves had AUCs of 0.79 (0.71-0.87) and 0.75 (0.59-0.91) respectively. Calibration curves were plotted to evaluate the consistency of the model, and the results showed that the predictive value of the nomogram model was similar to that of the actual one. Decision curves were plotted, which showed that the nomogram had higher positive net benefit in the range of 20% to 60%. This study suggest that serum IL-6, ICAM-1, and sST2 levels may serve as valuable prognostic indicators for wound healing progression in DF patients, with combined biomarker assessment showing potential clinical utility for outcome prediction. The total sample size (n = 210), with validation set (n = 63) of this study are relatively limited and the representativeness is restricted, which may affect the universality of the research conclusions.
100 项与 长沙晶易医药科技股份有限公司 相关的药物交易
登录后查看更多信息
100 项与 长沙晶易医药科技股份有限公司 相关的转化医学
登录后查看更多信息
组织架构
使用我们的机构树数据加速您的研究。
登录
或
管线布局
2025年09月18日管线快照
管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期
药物发现
1
10
临床前
临床申请
2
6
临床申请批准
临床1期
2
登录后查看更多信息
当前项目
登录后查看更多信息
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
营收
使用 Synapse 探索超过 36 万个组织的财务状况。
登录
或
科研基金(NIH)
访问超过 200 万项资助和基金信息，以提升您的研究之旅。
登录
或
投资
深入了解从初创企业到成熟企业的最新公司投资动态。
登录
或
融资
发掘融资趋势以验证和推进您的投资机会。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用